This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagihara, N. Articles by Youle, R. J. Search for Related Content PubMed PubMed Citation Articles by Hagihara, N. Articles by Youle, R. J.

Vascular Protection by Chloroquine during Brain Tumor Therapy with Tf-CRM107

Biochemistry and Clinical Sections, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke [N. H., S. W., E. H. O., R. J. Y.], and in Vivo NMR Research Center of National Institute of Neurological Disorders and Stroke [A. W. O.], National Institutes of Health, Bethesda, Maryland 20892

Tf-CRM107 is a conjugate of transferrin and a point mutant of diphtheria toxin that selectively kills cells expressing high levels of the transferrin receptor. Tf-CRM107 has been infused intratumorally into patients with malignant brain tumors. Although approximately half of the patients exhibit tumor responses, patients receiving higher doses of Tf-CRM107 may develop magnetic resonance image (MRI) evidence of toxicity indicative of small vessel thrombosis or petechial hemorrhage. Consistent with these clinical results we found that intracerebral injection of Tf-CRM107 into rats at total doses 0.025 µg causes brain damage detectable by MRI and histology. To widen the therapeutic window of Tf-CRM107, we explored ways to prevent this damage to the vasculature. We reasoned that the vasculature may be protected to a greater extent than tumor from Tf-CRM107 infused into brain parenchyma by i.v. injection of reagents with low blood-brain barrier permeability that block the toxicity of Tf-CRM107. Chloroquine, a well-characterized antimalarial drug, blocks the toxicity of diphtheria toxin and Tf-CRM107. Systemic administration of chloroquine blocked the toxicity of Tf-CRM107 infused intracerebrally in rats and changed the maximum tolerated dose of Tf-CRM107 from 0.2 to 0.3 µg. Moreover, chloroquine treatment completely blocked the brain damage detected by MRI caused by intracerebral infusion of 0.05 µg of Tf-CRM107. In nude mice bearing s.c. U251 gliomas, chloroquine treatment had little effect on the antitumor efficacy of Tf-CRM107. Thus, chloroquine treatment may be useful to reduce the toxicity of Tf-CRM107 for normal brain without inhibiting antitumor efficacy and increase the therapeutic window of Tf-CRM107 for brain tumor therapy.

This article has been cited by other articles:

				J. H. Sampson, D. A. Reardon, A. H. Friedman, H. S. Friedman, R. E. Coleman, R. E. McLendon, I. Pastan, and D. D. Bigner Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study Neuro-oncol, January 1, 2005; 7(1): 90 - 96. [Abstract] [PDF]

				T. F. Liu, P. D. Hall, K. A. Cohen, M. C. Willingham, J. Cai, A. Thorburn, and A. E. Frankel Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice Clin. Cancer Res., January 1, 2005; 11(1): 329 - 334. [Abstract] [Full Text] [PDF]

				T. F. Liu, S. B. Tatter, M. C. Willingham, M. Yang, J. J. Hu, and A. E. Frankel Growth Factor Receptor Expression Varies among High-Grade Gliomas and Normal Brain: Epidermal Growth Factor Receptor Has Excellent Properties for Interstitial Fusion Protein Therapy Mol. Cancer Ther., August 1, 2003; 2(8): 783 - 787. [Abstract] [Full Text] [PDF]

				Z. M. Qian, H. Li, H. Sun, and K. Ho Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway Pharmacol. Rev., December 1, 2002; 54(4): 561 - 587. [Abstract] [Full Text] [PDF]

				A. E. Frankel Increased Sophistication of Immunotoxins Clin. Cancer Res., April 1, 2002; 8(4): 942 - 944. [Full Text] [PDF]